JACOBIO-B (01167) announced that it will present preclinical data for its oral, highly potent Pan-KRAS inhibitor JAB-23E73 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held from October 22 to October 26, 2025, at the Hynes Convention Center in Boston, Massachusetts. The abstract titled “Preclinical Studies of the Oral, Absorbable, and Highly Potent Pan-KRAS (On/Off) Inhibitor JAB-23E73” will be made available through the conference app at noon (ET) on October 22, 2025, and will also be published as free supplementary content in the AACR journal, Molecular Cancer Therapeutics. The poster presentation for JAB-23E73 is scheduled for October 23, 2025, from 12:30 PM to 4 PM (ET).

JAB-23E73 demonstrates high potency and favorable oral bioavailability as a Pan-KRAS (On/Off) inhibitor, selectively targeting KRAS while avoiding inhibition of HRAS and NRAS. Data indicate that JAB-23E73 exhibits remarkable anti-tumor activity across various cancer types with different KRAS-driven mutations or amplifications. In mouse tumor models driven by KRAS, JAB-23E73 effectively induces tumor regression without causing significant weight changes, suggesting good tolerability and a broad therapeutic window. The pharmacokinetics of JAB-23E73 favor oral administration, controlling the inhibition of intratumoral p-ERK relative to its plasma concentrations. Phase I clinical trials of JAB-23E73 for advanced solid tumor patients carrying KRAS gene mutations are currently underway in China and the United States (NCT06959615, NCT06973564).